TW200306184A - Heterocyclic amide derivatives for the treatment of diabetes and other diseases - Google Patents

Heterocyclic amide derivatives for the treatment of diabetes and other diseases Download PDF

Info

Publication number
TW200306184A
TW200306184A TW092105025A TW92105025A TW200306184A TW 200306184 A TW200306184 A TW 200306184A TW 092105025 A TW092105025 A TW 092105025A TW 92105025 A TW92105025 A TW 92105025A TW 200306184 A TW200306184 A TW 200306184A
Authority
TW
Taiwan
Prior art keywords
group
compound
carbon atoms
item
substituted
Prior art date
Application number
TW092105025A
Other languages
English (en)
Chinese (zh)
Inventor
Magnus Pfahl
Catherine Tachdjian
Hussien A Al-Shamma
Andrea Fanjul Giachino
Karine Jakubowicz-Jaillardon
Guo Jianhua
Boudjelal Mohamed
W Zapf James
Original Assignee
Incyte San Diego Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte San Diego Inc filed Critical Incyte San Diego Inc
Publication of TW200306184A publication Critical patent/TW200306184A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW092105025A 2002-03-08 2003-03-07 Heterocyclic amide derivatives for the treatment of diabetes and other diseases TW200306184A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36270202P 2002-03-08 2002-03-08

Publications (1)

Publication Number Publication Date
TW200306184A true TW200306184A (en) 2003-11-16

Family

ID=27805215

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092105025A TW200306184A (en) 2002-03-08 2003-03-07 Heterocyclic amide derivatives for the treatment of diabetes and other diseases

Country Status (14)

Country Link
US (2) US7102000B2 (enExample)
EP (1) EP1487443A4 (enExample)
JP (1) JP2005530705A (enExample)
KR (1) KR20050006126A (enExample)
CN (1) CN1649586A (enExample)
AU (1) AU2003225682A1 (enExample)
CA (1) CA2478342A1 (enExample)
IL (1) IL163952A0 (enExample)
MX (1) MXPA04008733A (enExample)
NO (1) NO20044250L (enExample)
RU (1) RU2004129752A (enExample)
TW (1) TW200306184A (enExample)
WO (1) WO2003075924A1 (enExample)
ZA (1) ZA200408057B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016123A1 (en) 1999-08-31 2001-03-08 Maxia Pharmaceuticals, Inc. Benzylidene-thiazolidinediones and analogues and their use in the treatment of inflammation
US7153875B2 (en) * 2001-03-07 2006-12-26 Incyte San Diego Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
AU2002254171A2 (en) * 2001-03-08 2002-09-24 Incyte San Diego, Inc. RXR activating molecules
EP1421061A4 (en) * 2001-08-17 2004-12-22 Incyte San Diego Inc OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEROLEMIA
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
MXPA05011242A (es) * 2003-04-18 2006-07-06 Incyte San Diego Inc Compuestos isocromanos sustituidos para el tratamiento de trastornos metabolicos, cancer y otras enfermedades.
EP1566202A1 (en) * 2004-02-23 2005-08-24 Sahltech I Göteborg AB Use of resistin antagonists in the treatment of rheumatoid arthritis
US7122700B2 (en) 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
WO2006025551A1 (ja) * 2004-08-30 2006-03-09 Takeda Pharmaceutical Company Limited スクリーニング方法
US7638533B2 (en) 2005-09-30 2009-12-29 Janssen Pharmaceutica N.V. Dihydro-1[1H]-quinolin-2-one derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
CA2721459A1 (en) 2008-05-20 2009-11-26 Merck Sharp & Dohme Corp. Efficient production of heterologous proteins using mannosyl transferase inhibitors
WO2012153775A1 (ja) 2011-05-10 2012-11-15 国立大学法人神戸大学 Ras機能阻害作用を有するチオキソチアゾリジン誘導体
WO2015066647A2 (en) 2013-11-03 2015-05-07 The Regents Of The University Of California Ionic liquids for transdermal drug delivery
WO2017213116A1 (ja) * 2016-06-07 2017-12-14 三菱電機株式会社 温度推定方法
WO2018044920A1 (en) 2016-08-29 2018-03-08 The Regents Of The University Of California Topical formulations based on ionic species for skin treatment
US10828265B2 (en) 2016-12-09 2020-11-10 The Regents Of The University Of California Formulations of propranolol and analogs as an amorphous melt or ionic liquid for transdermal drug delivery

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051842A (en) 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
JPS5538359A (en) 1978-09-12 1980-03-17 Hamari Yakuhin Kogyo Kk Preparation of 2-(3-benzoylphenyl)-propionic acid
US4383529A (en) 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
IL72684A (en) 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4713244A (en) 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
CA1325222C (en) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
EP0304493B1 (en) 1987-03-11 1992-09-02 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene derivatives
JPS63230689A (ja) * 1987-03-18 1988-09-27 Tanabe Seiyaku Co Ltd ベンゾオキサジン誘導体
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US5330998A (en) 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5223522A (en) 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
IE62214B1 (en) 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
JP2671962B2 (ja) 1991-07-22 1997-11-05 ファイザー・インコーポレーテッド キラルチアゾリジン−2,4−ジオン誘導体の合成における中間体の製造方法
BR9306284A (pt) 1992-04-22 1998-01-13 Ligand Pharm Inc Compostos tendo seletividade pra receptores de retinóides x
US5780676A (en) 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
EP0915090A1 (en) 1992-09-10 1999-05-12 Eli Lilly And Company Compounds useful as hypoglycemic agents and for treating Alzheimer's disease
BR9307528A (pt) 1992-11-25 1999-08-31 Jolla Cancer Research Foudatio Processo para inspecionar subst‰ncia quanto à capacidade de afetar a formação de homodìmero em receptor de retinóide x, processo para inspecionar subst‰ncia quanto à capacidade de induzir seletivamente a formação de heterodìmero em receptor de retinóide x, processo para inspecionar subst‰ncia quanto à capacidade de afetar a capacidade de um homodìmero, em um receptor de retinóide x, se ligar ao dna, processo para inspecionar um elemento de resposta quanto à capacidade de se ligar a um homodìmero em receptor de retinóide x, homodìmero em receptor de retinóide x, composto aromático bicìclico, processo para inibir atividade de heterodìmero em receptor de retinóide x, processo para promover transcrição de um gene ativado por homodìmero em receptor de retinóide em uma célula, processo para inibir atividade de homodìmero em receptor de retinóide x, processo para determinar maior probabilidade de patologia, processo para tratar patologia, processo para ativar seletivamente formação de homodìmero em receptor de retinóide x em uma célula, processo para promover a formação de homodìmero em receptor de retinóide x em uma célula, composição farmacêutica, processo para modular expressão de gene, e processo para tratar paciente
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
AU692839B2 (en) 1994-02-17 1998-06-18 American Home Products Corporation Substituted biphenyl derivatives as phosphodiesterase inhibitors
US5691376A (en) 1994-02-17 1997-11-25 American Home Products Corporation Substituted biphenyl derivatives
JPH09136877A (ja) 1995-06-16 1997-05-27 Takeda Chem Ind Ltd 複素環化合物、その製造法及び用途
AU701790B2 (en) 1995-07-17 1999-02-04 Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) Method for treating cancers using 6-{3-{1-adamantyl}- 4-hydroxyphenyl}
JPH09176162A (ja) 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
CN1196730A (zh) 1996-06-19 1998-10-21 雷迪博士研究基金会 具有增强的抗糖尿病活性的穴糖酮的新的多晶型形式及其制备方法
CA2259936C (en) 1996-07-08 2009-02-03 Magnus Pfahl Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents
CA2300813A1 (en) 1997-08-21 1999-03-04 Hiroyuki Odaka Anti-inflammatory agent
JP4398585B2 (ja) 1997-11-12 2010-01-13 有限会社ケムフィズ レチノイドレセプター作用剤
US6262044B1 (en) 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
AU743411B2 (en) 1998-08-21 2002-01-24 Viropharma Incorporated Compounds, compositions and methods for treating or preventing viral infections and associated diseases
AU6330999A (en) 1998-09-30 2000-04-17 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
WO2000032598A1 (en) 1998-12-04 2000-06-08 Structural Bioinformatics Inc. Methods and compositions for treating inflammatory diseases utilizing inhibitors of tumor necrosis factor activity
WO2000063196A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
WO2001016123A1 (en) 1999-08-31 2001-03-08 Maxia Pharmaceuticals, Inc. Benzylidene-thiazolidinediones and analogues and their use in the treatment of inflammation
EP1142885B1 (en) 1999-11-12 2006-11-15 Fujimoto Brothers Co., Ltd. 2-(n-cyanoimino)thiazolidin-4-one derivatives
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
US7153875B2 (en) 2001-03-07 2006-12-26 Incyte San Diego Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
AU2002254171A2 (en) 2001-03-08 2002-09-24 Incyte San Diego, Inc. RXR activating molecules
EP1373240B1 (en) 2001-03-14 2005-06-15 Eli Lilly And Company Retinoid x receptor modulators
EP1392326B1 (en) 2001-04-04 2009-09-09 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
EP1421061A4 (en) 2001-08-17 2004-12-22 Incyte San Diego Inc OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEROLEMIA
US7071218B2 (en) 2001-11-15 2006-07-04 Incyte San Diego Incorporated N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases
TW200304375A (en) 2001-12-06 2003-10-01 Maxia Pharmaceuticals Inc 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US20050014767A1 (en) 2003-01-29 2005-01-20 Magnus Pfahl Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
MXPA05011242A (es) 2003-04-18 2006-07-06 Incyte San Diego Inc Compuestos isocromanos sustituidos para el tratamiento de trastornos metabolicos, cancer y otras enfermedades.

Also Published As

Publication number Publication date
JP2005530705A (ja) 2005-10-13
KR20050006126A (ko) 2005-01-15
CA2478342A1 (en) 2003-09-18
EP1487443A1 (en) 2004-12-22
US20060241138A1 (en) 2006-10-26
US7102000B2 (en) 2006-09-05
EP1487443A4 (en) 2006-04-12
IL163952A0 (en) 2005-12-18
AU2003225682A2 (en) 2003-09-22
NO20044250L (no) 2004-11-03
CN1649586A (zh) 2005-08-03
MXPA04008733A (es) 2006-07-03
WO2003075924A1 (en) 2003-09-18
ZA200408057B (en) 2007-05-30
US20030216432A1 (en) 2003-11-20
AU2003225682A1 (en) 2003-09-22
RU2004129752A (ru) 2005-05-10

Similar Documents

Publication Publication Date Title
ES2248107T3 (es) Benciliden-tiazolidindionas y analogos y su utilizacion en el tratamiento de la diabetes.
TW200306184A (en) Heterocyclic amide derivatives for the treatment of diabetes and other diseases
TWI277415B (en) Bicyclic heterocycles for the treatment of diabetes and other diseases
CN115244056A (zh) 稠合咪唑类衍生物、其制备方法及其在医药上的应用
CN108047201A (zh) 作为AXL和c-MET激酶抑制剂的尿嘧啶衍生物
WO2006046593A1 (ja) 2以上の置換基を有するベンゼン化合物
HUT57752A (en) Process for producing thiazole derivatives and pharmaceutical compositions comprising same
WO2008066097A1 (fr) Dérivé d'acide carboxylique
WO2008016175A1 (en) Activator for peroxisome proliferator activated receptor
KR20150079968A (ko) 헤테로아릴 유도체 및 그의 용도
CN107108525A (zh) 用作Lp‑PLA2抑制剂的嘧啶酮类化合物及其药物组合物
KR20220143062A (ko) 신규 ep4 길항제의 합성 및 암과 염증에서의 이의 용도
TW200530223A (en) Heteroaryl derivatives as PPAR activators
JP2006523724A (ja) 代謝障害、癌および他の疾患の治療のための置換イソクロマン化合物
WO2006109633A1 (ja) 置換インドール化合物
JP2013538870A (ja) 新規gpr119アゴニスト
JPS61100579A (ja) ピリジン誘導体
WO2022233302A1 (zh) 嘧啶酮衍生物、其制备方法、药物组合物和用途
JP2007509039A (ja) シクロペンテン化合物
WO2007004733A1 (ja) ペルオキシソーム増殖剤活性化受容体δの活性化剤
JP3985121B2 (ja) ジヒドロキノリン誘導体
JP2009503007A (ja) フェニルピリジン誘導体、それらの製造、及び医薬品としての使用
EP1593677A2 (en) Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
KR20210085369A (ko) Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물 및 이의 용도
WO2003078422A1 (en) Novel pyridone derivative